Na Eun Kim, Rajam S Raghunathan, Elena G Hughes, Xochitl R Longstaff, Chi-Hong Tseng, Shanpeng Li, Dianne S Cheung, Yaroslav A Gofnung, Pouyan Famini, James X Wu, Michael W Yeh, Masha J Livhits
CONTEXT: Molecular testing has improved risk stratification and increased nonoperative management for patients with indeterminate thyroid nodules, but data on the long-term outcomes of current molecular tests Afirma Gene Sequencing Classifier (GSC) and Thyroseq v3 are limited. OBJECTIVE: To determine the rate of delayed operation and the false negative rate of the Afirma GSC and Thyroseq v3 in Bethesda III and IV thyroid nodules. METHODS: Prospective follow-up of a single center, randomized, clinical trial comparing the performance of Afirma GSC and Thyroseq v3 in the diagnosis of indeterminate thyroid nodules at the University of California, Los Angeles (UCLA)...
August 18, 2023: Journal of Clinical Endocrinology and Metabolism